Patrick M Winter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/466876/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With α _v β ₃ -Integrin–Targeted Nanoparticles. Circulation, 2003, 108, 2270-2274.	1.6	691
2	Novel MRI Contrast Agent for Molecular Imaging of Fibrin. Circulation, 2001, 104, 1280-1285.	1.6	540
3	Endothelial α ν β 3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2103-2109.	2.4	382
4	Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Research, 2003, 63, 5838-43.	0.9	323
5	Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent. Circulation, 2002, 106, 2842-2847.	1.6	274
6	Molecular MR imaging of melanoma angiogenesis with ???3-targeted paramagnetic nanoparticles. Magnetic Resonance in Medicine, 2005, 53, 621-627.	3.0	266
7	A Novel Europium(III)-Based MRI Contrast Agent. Journal of the American Chemical Society, 2001, 123, 1517-1518.	13.7	257
8	Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magnetic Resonance in Medicine, 2004, 51, 480-486.	3.0	252
9	Quantitative ?magnetic resonance immunohistochemistry? with ligand-targeted19F nanoparticles. Magnetic Resonance in Medicine, 2004, 52, 1255-1262.	3.0	200
10	Improved molecular imaging contrast agent for detection of human thrombus. Magnetic Resonance in Medicine, 2003, 50, 411-416.	3.0	195
11	Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. Journal of Magnetic Resonance Imaging, 2007, 25, 667-680.	3.4	186
12	Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 435-441.	2.4	153
13	Antiangiogenic Synergism of Integrin-Targeted Fumagillin Nanoparticles and Atorvastatin in Atherosclerosis. JACC: Cardiovascular Imaging, 2008, 1, 624-634.	5.3	142
14	Magnetic resonance molecular imaging with nanoparticles. Journal of Nuclear Cardiology, 2004, 11, 733-743.	2.1	125
15	Minute dosages of α <i>_{ν<}</i> β ₃ â€ŧargeted fumagillin nanoparticles impair Vxâ€2 tumor angiogenesis and development in rabbits. FASEB Journal, 2008, 22, 2758-2767.	0.5	102
16	Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magnetic Resonance in Medicine, 2006, 56, 1384-1388.	3.0	97
17	Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis, 2010, 13, 189-202.	7.2	95
18	In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla. Investigative Radiology, 2006, 41, 305-312.	6.2	93

PATRICK M WINTER

#	Article	IF	CITATIONS
19	Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Medicinal Chemistry, 2010, 2, 471-490.	2.3	88
20	Gadoliniumâ€modulated ¹⁹ F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magnetic Resonance in Medicine, 2008, 60, 1066-1072.	3.0	86
21	Emerging nanomedicine opportunities with perfluorocarbon nanoparticles. Expert Review of Medical Devices, 2007, 4, 137-145.	2.8	67
22	1H/19F Magnetic Resonance Molecular Imaging with Perfluorocarbon Nanoparticles. Current Topics in Developmental Biology, 2005, 70, 57-76.	2.2	62
23	Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine, 2006, 1, 321-329.	3.3	61
24	Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. International Journal of Nanomedicine, 2007, 2, 515-26.	6.7	61
25	Molecular Imaging of Human Thrombus with Computed Tomography. Academic Radiology, 2005, 12, S9-S13.	2.5	58
26	TmDOTP5- as a23Na shift reagent for the subcutaneously implanted 9L gliosarcoma in rats. Magnetic Resonance in Medicine, 2001, 45, 436-442.	3.0	57
27	Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magnetic Resonance in Medicine, 2008, 60, 1353-1361.	3.0	55
28	Molecular imaging of angiogenic therapy in peripheral vascular disease with α _{μ2} ̲ ₃ â€integrinâ€targeted nanoparticles. Magnetic Resonance in Medicine, 2010, 6 369-376.	54,3.0	55
29	Novel Paramagnetic Contrast Agents for Molecular Imaging and Targeted Drug Delivery. Current Pharmaceutical Biotechnology, 2004, 5, 495-507.	1.6	48
30	Antiâ€angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 311-323.	6.1	45
31	An MRI system for imaging neonates in the NICU: initial feasibility study. Pediatric Radiology, 2012, 42, 1347-1356.	2.0	43
32	Improved paramagnetic chelate for molecular imaging with MRI. Journal of Magnetism and Magnetic Materials, 2005, 293, 540-545.	2.3	42
33	Quantitation of intracellular [Na ⁺] in vivo by using TmDOTP ^{5â~} as an NMR shift reagent and extracellular marker. Jou 1998, 85, 1806-1812.	rna ł.o f Ap	plie®&Physiolog
34	Molecular Imaging and Targeted Drug Delivery with a Novel, Ligand-Directed Paramagnetic Nanoparticle Technology. Academic Radiology, 2002, 9, S330-S331.	2.5	38
35	Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Review of Cardiovascular Therapy, 2005, 3, 705-715.	1.5	38
36	Molecular imaging by MRI. Current Cardiology Reports, 2006, 8, 65-69.	2.9	38

PATRICK M WINTER

#	Article	IF	CITATIONS
37	Molecular MR Imaging of Neovascular Progression in the Vx2 Tumor with αvβ3-Targeted Paramagnetic Nanoparticles. Radiology, 2013, 268, 470-480.	7.3	37
38	Triple-Quantum-Filtered 23Na NMR Spectroscopy of Subcutaneously Implanted 9L Gliosarcoma in the Rat in the Presence of TmDOTP5â''. Journal of Magnetic Resonance, 2001, 152, 70-78.	2.1	33
39	Nanomedicine Opportunities in Cardiology. Annals of the New York Academy of Sciences, 2006, 1080, 451-465.	3.8	33
40	Angiogenesis imaging with vascular-constrained particles: the why and how. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 114-126.	6.4	33
41	Targeted Magnetic Resonance Imaging Contrast Agents. , 2006, 124, 387-400.		29
42	MR Molecular Imaging of Aortic Angiogenesis. JACC: Cardiovascular Imaging, 2010, 3, 824-832.	5.3	26
43	Spectral properties of a bifunctional PARACEST europium chelate: an intermediate for targeted imaging applications. Contrast Media and Molecular Imaging, 2007, 2, 55-58.	0.8	25
44	Quantitative cardiovascular magnetic resonance for molecular imaging. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 62.	3.3	20
45	Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2012, 4, 389-398.	6.1	16
46	Perfluorocarbon Nanoparticles: Evolution of a Multimodality and Multifunctional Imaging Agent. Scientifica, 2014, 2014, 1-10.	1.7	16
47	Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine. Journal of Magnetic Resonance Imaging, 2015, 41, 1079-1087.	3.4	16
48	Quantification of water exchange kinetics for targeted PARACEST perfluorocarbon nanoparticles. NMR in Biomedicine, 2012, 25, 279-285.	2.8	12
49	Assessment of tumor angiogenesis: dynamic contrastâ€enhanced MRI with paramagnetic nanoparticles compared with Gdâ€DTPA in a rabbit Vxâ€2 tumor model. Contrast Media and Molecular Imaging, 2010, 5, 155-161.	0.8	9
50	Initial investigation of a novel noninvasive weight loss therapy using MRIâ€Guided high intensity focused ultrasound (MRâ€HIFU) of visceral fat. Magnetic Resonance in Medicine, 2016, 76, 282-289.	3.0	6
51	Nanotechnologies for Cellular and Molecular Imaging by MRI. , 2005, , 227-249.		5
52	Diagnostic and Therapeutic Targeted Perfluorocarbon Nanoparticles. , 0, , 365-380.		0
53	Research Highlights. Nanomedicine, 2011, 6, 1305-1308.	3.3	0
54	Magnetic Resonance Molecular Imaging of Plaque Angiogenesis. Current Cardiovascular Imaging Reports, 2012, 5, 36-44.	0.6	0

PATRICK M WINTER

#	Article	IF	CITATIONS
55	Editorial for "Nonâ€enhanced Chemical Exchange Saturation Transfer Cardiac Magnetic Resonance Imaging in Patients With Amyloid Light Chain Amyloidosis― Journal of Magnetic Resonance Imaging, 2022, 55, 577-578.	3.4	0
56	Targeted nanoparticle contrast agents for vascular molecular imaging and therapy. , 2007, , 289-302.		0
57	Magnetic Resonance Molecular Imaging and Targeted Therapeutics. , 2008, , 649-672.		0
58	Molecular Imaging at Nanoscale with Magnetic Resonance Imaging. , 2014, , 75-102.		0
59	Perfluorocarbon Nanoparticles. , 2016, , 3143-3156.		0
60	Molecular MR Imaging with Paramagnetic Perfluorocarbon Nanoparticles. , 2008, , 163-182.		0
61	Tuning of the drug delivery vehicle. Nanomedicine, 2011, 6, 1306.	3.3	0
62	Improving the homogeneity of DNA patterning on microarrays. Nanomedicine, 2011, 6, 1306-7.	3.3	0
63	Targeted nanoparticles for phototherapy. Nanomedicine, 2011, 6, 1307.	3.3	0
64	Advantages of a positive surface charge. Nanomedicine, 2011, 6, 1308.	3.3	0